Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

85.04
-1.4900-1.72%
Pre-market: 85.500.4600+0.54%08:00 EDT
Volume:1.48M
Turnover:126.09M
Market Cap:16.61B
PE:19.47
High:87.00
Open:87.00
Low:84.90
Close:86.53
52wk High:87.24
52wk Low:53.56
Shares:195.28M
Float Shares:163.04M
Volume Ratio:0.91
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.37
EPS(LYR):0.1575
ROE:24.30%
ROA:11.52%
PB:3.98
PE(LYR):540.02

Loading ...

Incyte’s Phase 1 Study on INCB086550: A Potential Breakthrough in Cancer Treatment

TIPRANKS
·
Aug 12

Incyte’s Phase 3 Study on Povorcitinib: A Potential Game-Changer for Prurigo Nodularis

TIPRANKS
·
Aug 09

Incyte’s Rollover Study on Povorcitinib: Key Insights for Investors

TIPRANKS
·
Aug 09

Merus NV Reports Q2 2025 Revenue Increase of $1.5 Million, Driven by Higher Collaboration Sales

Reuters
·
Aug 08

BRIEF-Incyte Corp - CFO Christiana Stamoulis To Step Down September 16 - SEC Filing

Reuters
·
Aug 07

Incyte Corporation CFO Christiana Stamoulis Announces Departure to Pursue New Opportunity, Effective September 16, 2025

Reuters
·
Aug 07

Top Incyte Executive Sells Hundreds of Shares!

TIPRANKS
·
Aug 07

Sheila A. Denton, EVP & General Counsel, Reports Disposal of Incyte Corporation Common Shares

Reuters
·
Aug 07

Eaton Corporation Plc : Wells Fargo Raises Target Price to $375 From $360

THOMSON REUTERS
·
Aug 06

Actuate, Incyte, University of Pittsburgh collaborate on elraglusib trial

TIPRANKS
·
Aug 06

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

GlobeNewswire
·
Aug 06

Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Simply Wall St.
·
Aug 06

Incyte Corporation : Wells Fargo Raises to Overweight From Equal Weight

THOMSON REUTERS
·
Aug 06

Incyte: Reaffirms Full Year Financial Guidance

THOMSON REUTERS
·
Aug 06

Argus Research Adjusts Incyte Price Target to $90 From $75

MT Newswires Live
·
Aug 05

Incyte Corp. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Aug 05

Knight Therapeutics Expands Partnership with Incyte to Distribute Retifanlimab and Axatilimab in Latin America

Reuters
·
Aug 05

Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America

THOMSON REUTERS
·
Aug 05

Incyte Corp - Knight Gains Exclusive Rights to Distribute Retifanlimab and Axatilimab in Latam

THOMSON REUTERS
·
Aug 05

Syndax Pharmaceuticals Reports Q2 2025 Net Loss of $71.8M, EPS of $0.83; Revuforj Sales Surge 43% Over Q1 2025

Reuters
·
Aug 05